Business A Chinese COVID Delta variant vaccine maker gets a boost Published 3 years ago on 5 November 2021 By Terry Power Share Tweet Clover Biopharmaceuticals gets a $2 billion valuation on the hopes of a Delta-effective vaccine Read More Related Topics:boostChineseClover Biopharmaceuticals gets a $2 billion valuation on the hopes of a Delta-effective vaccineCOVIDDeltamakervaccinevariant Up Next When it comes to clinical trials, healthcare’s diversity problem is standing in the way of medical advancement Don't Miss The ‘bro culture’ accusations against electric vehicle startup Rivian ticks every box on the toxic workplace checklist Continue Reading You may like Decoding the data of the Chinese mpox outbreak China is suddenly dealing with another public health crisis: mpox The Download: Meta’s new AI system, and covert Chinese social media activity Spotting Chinese state media social accounts continues to be a challenge Covid hasn’t entirely gone away—here’s where we stand Mpox Cases Surge Globally, Sparking Vaccine Access Concerns Business These fast-growing Sun Belt cities suffer from high inflation Published 3 years ago on 4 May 2022 By Terry Power U.S. migration hotspots tend to have the highest inflation | Fortune You need to enable JavaScript to view this site. Continue Reading Business The U.S. is seizing a $325 million helipad-equipped megayacht in Fiji. The question is which Russian oligarch it belongs to Published 3 years ago on 4 May 2022 By Terry Power Oligarch sanctions: U.S. seizing $325 million megayacht in Fiji. The question is which Russian billionaire it belongs to | Fortune You need to enable JavaScript to view this site. Continue Reading Business Investors bank on today’s ‘once-in-a-generation’ Fed hike to be one of several Published 3 years ago on 4 May 2022 By Terry Power Fed rate hike: decision day rattles markets as investors worry that a giant ‘once-in-a-generation’ hike will be one of several this year | Fortune You need to enable JavaScript to view this site. Continue Reading